Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical behaviors. Large databases like the Surveillance, Epidemiology, and End Results (SEER) program and national NEN registries have provided significant epidemiological knowledge, but they have limitations given the recent advancements in NEN diagnostics and treatments. For instance, newer imaging techniques and therapies have revolutionized NEN management, rendering older data less representative. Additionally, crucial parameters, like the Ki67 index, are missing from many databases. Acknowledging these gaps, the Italian Association for Neuroendocrine Tumors (Itanet) initiated a national multicenter prospective database in 2019, aiming to gather data on newly-diagnosed gastroenteropancreatic neuroendocrine (GEP) NENs. This observational study, coordinated by Itanet, includes patients from 37 Italian centers. The database, which is rigorously maintained and updated, focuses on diverse parameters including age, diagnostic techniques, tumor stage, treatments, and survival metrics. As of October 2023, data from 1,600 patients have been recorded, with an anticipation of reaching 3600 by the end of 2025. This study aims at understanding the epidemiology, clinical attributes, and treatment strategies for GEP-NENs in Italy, and to introduce the Itanet database project. Once comprehensive follow-up data will be acquired, the goal will be to discern predictors of treatment outcomes and disease prognosis. The Itanet database will offer an unparalleled, updated perspective on GEP-NENs, addressing the limitations of older databases and aiding in optimizing patient care.
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database / Panzuto, Francesco; Partelli, Stefano; Campana, Davide; de Braud, Filippo; Spada, Francesca; Cives, Mauro; Tafuto, Salvatore; Bertuzzi, Alexia; Gelsomino, Fabio; Bergamo, Francesca; Marcucci, Stefano; Mastrangelo, Laura; Massironi, Sara; Appetecchia, Marialuisa; Filice, Angelina; Badalamenti, Giuseppe; Bartolomei, Mirco; Amoroso, Vito; Landoni, Luca; Rodriquenz, Maria Grazia; Valente, Monica; Colao, Annamaria; Isidori, Andrea; Fanciulli, Giuseppe; Bollina, Roberto; Ciola, Michele; Butturini, Giovanni; Marconcini, Riccardo; Arvat, Emanuela; Cinieri, Saverio; Berardi, Rossana; Baldari, Sergio; Riccardi, Ferdinando; Spoto, Chiara; Giuffrida, Dario; Gattuso, Domenico; Ferone, Diego; Rinzivillo, Maria; Bertani, Emilio; Versari, Annibale; Zerbi, Alessandro; Lamberti, Giuseppe; Lauricella, Eleonora; Pusceddu, Sara; Fazio, Nicola; Dell’Unto, Elisabetta; Marini, Marco; Falconi, Massimo. - In: ENDOCRINE. - ISSN 1559-0100. - 84:1(2024), pp. 42-47. [10.1007/s12020-023-03649-4]
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database
Berardi, Rossana;
2024-01-01
Abstract
Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical behaviors. Large databases like the Surveillance, Epidemiology, and End Results (SEER) program and national NEN registries have provided significant epidemiological knowledge, but they have limitations given the recent advancements in NEN diagnostics and treatments. For instance, newer imaging techniques and therapies have revolutionized NEN management, rendering older data less representative. Additionally, crucial parameters, like the Ki67 index, are missing from many databases. Acknowledging these gaps, the Italian Association for Neuroendocrine Tumors (Itanet) initiated a national multicenter prospective database in 2019, aiming to gather data on newly-diagnosed gastroenteropancreatic neuroendocrine (GEP) NENs. This observational study, coordinated by Itanet, includes patients from 37 Italian centers. The database, which is rigorously maintained and updated, focuses on diverse parameters including age, diagnostic techniques, tumor stage, treatments, and survival metrics. As of October 2023, data from 1,600 patients have been recorded, with an anticipation of reaching 3600 by the end of 2025. This study aims at understanding the epidemiology, clinical attributes, and treatment strategies for GEP-NENs in Italy, and to introduce the Itanet database project. Once comprehensive follow-up data will be acquired, the goal will be to discern predictors of treatment outcomes and disease prognosis. The Itanet database will offer an unparalleled, updated perspective on GEP-NENs, addressing the limitations of older databases and aiding in optimizing patient care.File | Dimensione | Formato | |
---|---|---|---|
Panzuto_Epidemiology-gastroenteropancreatic-neuroendocrine-neoplasms_2024.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Creative commons
Dimensione
449 kB
Formato
Adobe PDF
|
449 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.